CONMED (CNMD) vs InMode (INMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CONMED (CNMD) has outperformed InMode (INMD) over the past year, losing 3.0% versus a loss of 6.4%. Over five years, CNMD leads with a -68.2% price change compared with -83.1% for INMD. CONMED is the larger company by market cap ($1.35 billion vs $810.2 million), about 1.7 times the size.
On valuation, CONMED trades at a lower forward P/E (9.4x vs 10.3x for InMode). CONMED pays a dividend yielding 0.44%, while InMode does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | INMD |
|---|---|---|
| Share price | $45.11 | $14.08 |
| Market cap | $1.35B | $810.22M |
| 1-day change | +1.99% | +0.50% |
| YTD return | +11.11% | -4.15% |
| 1-year return | -3.03% | -6.45% |
| 5-year return | -68.24% | -83.11% |
| P/E ratio (TTM) | 24.38 | 11.64 |
| Forward P/E | 9.43 | 10.26 |
| EPS (TTM) | $1.85 | $1.21 |
| Dividend yield | 0.44% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| 52-week high | $53.66 | $16.67 |
| 52-week low | $31.44 | $12.72 |
| Distance from 52-week high | -15.93% | -15.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +0.86% | +14.84% |
| Average volume | 493.66K | 501.37K |
| Shares outstanding | 29.95M | 57.54M |
| Employees | 3,900 | 660 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CONMED trades at a higher earnings multiple (24.4x vs 11.6x trailing P/E).
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
CNMD vs INMD FAQ
Which is bigger, CONMED or InMode?
CONMED (CNMD) is larger, with a market capitalization of $1.35B compared with $810.22M for InMode (INMD).
Which stock has performed better over the past year, CNMD or INMD?
CNMD returned -3.03% over the past 12 months, compared with -6.45% for INMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CNMD or INMD?
INMD has the lower trailing P/E at 11.6, versus 24.4 for CNMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, CONMED or InMode?
CONMED pays a dividend yielding 0.44%, while InMode does not currently pay a regular dividend.
Are CONMED and InMode in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.